Disclaimer This presentation is prepared by Omkar Speciality - - PowerPoint PPT Presentation

2

Disclaimer

This presentation is prepared by Omkar Speciality Chemicals Limited (OSCL or the “Company”) for general information purposes only, without regard to specific objectives, suitability, financial situations and needs of any particular person and does not constitute any recommendation or form part of any offer or invitation or inducement to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities of the Company, nor shall it or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any contract or commitment thereof. This presentation does not solicit any action based on the material contained herein. Nothing in this presentation is intended by the Company to be construed as legal, accounting or tax advice. This presentation has been prepared by the Company based upon information available in the public domain and its internal estimates. This presentation has not been approved and will not or may not be reviewed or approved by any statutory or regulatory authority in India or by any Stock Exchange in India. This presentation may include statements which may constitute forward-looking statements. The actual results could differ materially from those projected in any such forward-looking statements because of various factors. The Company assumes no responsibility to publicly amend, modify or revise any forward-looking statements, on the basis of any subsequent developments, information or events, or otherwise. The information contained in these materials has not been independently verified. None of the Company, its Directors or Promoter(s) or affiliates, nor any of its or their respective employees, advisers or representatives or any other person accepts any responsibility or liability whatsoever, whether arising in tort, contract or otherwise, for any errors, omissions or inaccuracies in such information or opinions or for any loss, cost or damage suffered or incurred howsoever arising, directly or indirectly, from any use of this document or its contents or

• therwise in connection with this document, and makes no representation or warranty, express or implied, for the contents of this document including its accuracy, fairness,

completeness or verification or for any other statement made or purported to be made by any of them, or on behalf of them, and nothing in this document or at this presentation shall be relied upon as a promise or representation in this respect, whether as to the past or the future. Past performance is not a guide for future performance. The information contained in this presentation are current, and if not stated otherwise, made as of the date of this presentation. The Company undertake no obligation to update or revise any information in this presentation as a result of new information, future events or otherwise. Any person / party intending to provide finance / invest in the shares / businesses of the Company shall do so after seeking their own professional advice and after carrying out their own due diligence procedure to ensure that they are making an informed decision. By attending/perusing this presentation you acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future business of the Company. This presentation is strictly confidential and may not be copied or disseminated, in whole or in part, and in any manner or for any purpose. No person is authorised to give any information or to make any representation not contained in or inconsistent with this presentation and if given or made, such information or representation must not be relied upon as having been authorized by any person. Failure to comply with this restriction may constitute a violation of the applicable securities laws. This presentation is not intended for distribution

• r publication in the United States. Neither this document nor any part or copy of it may be distributed, directly or indirectly, in the United States. The distribution of this document in

certain jurisdictions may be restricted by law and persons into whose possession this presentation comes should inform themselves about and observe any such restrictions. By participating in this presentation or by reviewing this presentation, you agree to be bound by the foregoing limitations. This document contains certain forward-looking statements relating to the business, financial performance, strategy and results of the Company and/or the industry in which it operates. Forward-looking statements are statements concerning future circumstances and results, and any other statements that are not historical facts, sometimes identified by the words "believes", "expects", "predicts", "intends", "projects", "plans", "estimates", "aims", "foresees", "anticipates", "targets", and similar expressions. The forward-looking statements, including those cited from third party sources, contained in this presentation are based on numerous assumptions and are uncertain and subject to risks. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Neither the Company nor its affiliates or advisors or representatives nor any of its or their parent or subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this presentation or the actual occurrence of the forecasted developments. Forward-looking statements speak only as of the date of this presentation. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this presentation as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward looking statements are based. This presentation is not an offer to sell or a solicitation of any offer to buy the securities of the Company in the United States or in any other jurisdiction where such offer or sale would be unlawful. Securities may not be offered, sold, resold, pledged, delivered, distributed or transferred, directly or indirectly, into or within the United States absent registration under the Securities Act, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States. The Company’s securities have not been and will not be registered under the Securities Act. The Company’s financial year ends on March 31.

3

Company Overview

• Omkar Speciality Chemicals Ltd (OSCL) is

involved in the manufacturing of inorganic and

• rganic

intermediates and Active Pharmaceuticals Ingredients (APIs)

• OSCL has nine units in the state of

Maharashtra, India (five units in Badlapur, District Thane, three units in Chiplun, District Ratnagiri and one unit in Mahad, District Raigad)

• The Company’s product segments include

Iodine Compounds, Selenium Compounds, Intermediates, Resolving Agents and Others (Molybdenum, Cobalt, and Bismuth) and APIs which comprises of more than 200 products

• Exports to about 38 countries, including

regulated markets such as Europe, North America, South America, China and other Asian countries Financial Snapshot FY12 FY13 FY14 FY15 Revenue (Rs.Cr.) 166.9 211.7 240.3 265.13 EBITDA (Rs.Cr.) 33.2 40.2 42.9 52.17 Margin 19.9% 19.0% 17.9% 19.68% PAT (Rs.Cr.) 16.0 20.6 13.6 24.28 Margin 9.4% 9.5% 5.6% 9.13% Net worth (Rs.Cr.) 105.4 127.0 137.2 168.57

Note: EBITDA calculated as PBT + Depreciation + Finance Costs – Other Income

OSCL Lasa Laboratory

• Pvt. Ltd.

Urdhwa Chemicals Company Pvt. Ltd. Rishichem Research Limited Desh Chemicals

• Pvt. Ltd.

SITE LOCATIONS

Badlapur Mahad Chiplun Mumbai JNPT port

Badlapur

• Unit I
• Unit II
• Unit III
• Unit IV
• Rishichem

Chiplun

• Unit V
• Unit VI
• Urdhwa

Mahad

• Lasa

5

Promoters & Directors

• Mr. Pravin Herlekar

Chairman & Managing Director

• He is a Bachelor of Technology in Chemical Engineering from Indian Institute of Technology,

Bombay and is a post graduate in management studies from Mumbai University

• He has an overall experience of 40 years in the field of Product Development, Marketing and

Administration

• He has been actively involved in the business of the Company and has played a key role in the

growth of OSCL with his inputs in strategic planning and business development

• Over the years he has been successful in expanding OSCL’s customer base, especially in

Europe, North America, Asia, South America & Australia

• Mr. Omkar Herlekar

Whole-time Director

• He is a Bachelor of Science and Master of Science (By Research) in Chemistry from the

University of Mumbai and has an overall experience of 8 years

• He looks after the Research & Development activities of OSCL and supervises the entire

factory operations

• He is actively involved in the setting up and implementation of OSCL’s new manufacturing

units

6

Directors

• Prof. Dr. Suhas Rane

Independent Director

He is a BE Mechanical Engineer, Diploma in Management Studies (DMS)and Master of Financial Management (MFM) from Mumbai University. He has a Ph.D. in supply Chain Management from University of Pune. He has an overall experience of 41 years. Currently he is a visiting faculty with NMIMS, S.P. Jain — Singapore & Dubai, Indo-German Chamber

• f Commerce and ICFAI
• Mrs. Anjali Herlekar

Non-executive,

Promoter And Woman Director

Bachelor of Science (Physics) and Master of Education from University of Mumbai. She has an

• verall experience of about 20 years in the field of

policy matters & HR administration in addition to her experience in Education.

• Mr. Sitendu Shamra

Independent Director

• Dr. Vikas Telvekar

Independent Director

He is an eminent Chartered Accountant. He has

• ver 25 years of experience in the area of

finance, tax planning, service tax etc. He has been practicing as a Chartered Accountant, in Mumbai, under the firm name Sitendu Sharma & Company. He is a Master of Science (Technology) and Doctor of Philosophy (Technology) in Pharmaceutical and Fine Chemicals from UDCT, Mumbai. Since 2003, he is associated with The Institute of Chemical Technology, Department of Pharmaceutical Science and Technology as a permanent faculty. Recently Department of Science and Technology (DST), Government of India awarded him the BOYSCAST fellowship

• Mr. Subhash Mali

Independent Director

He is a Bachelor of Chemical Engineering from University of Bombay. He has an overall experience of about 36 years. During his tenure he has worked with Asian Paints Limited, Ranbaxy Laboratories Limited, Unichem Laboratories Limited and Kopran Limited. Since 2002, he is employed with Arch Pharmalabs Limited, Mumbai as Technical Director

• Mr. Rishikesh Herlekar

Executive Director

He is a B.E. (Chemical Engg.). and Pursuing M. Tech in Pharmaceutical Sciences. He has an overall experience of 2 years in the Business Development and also involved in Accounting, Audit & Finance area, Coordinating with Production, Quality Production, Quality Assurance and related Regulatory Matters.

7

Directors

• Mr. Subhash Ghalke

Independent Director

He is a B.Tech from IIT Bombay and M. Tech from IIT Kanpur. He has an overall experience of about 36 years. During his tenure he has worked with Aegis Chemical, Colgate Palmilive India, Lime Chemicals, UHDE India, Jayant Oils and Derivatives, Chemtrols

• Ltd. etc.
• Mrs. Sanjivani

Patare Independent and Woman Director

• Mr. Prakash Rao

Executive Director

She is a B.com graduate and Law Graduate from Pune University. She has over 20 years of experience in the area of Conveyance Matters, legal matters and procedural work. He is a B.com. Graduate from Mumbai University. He has overall 30 years of experience in the field of HR, Admin and Public Relations.

• Mr. Vikas Gadre

Independent Director

He is a B.Tech. from IIT Bombay, MBA from IIM, Banglaore and Company Secretary from ICSI. He has an overall experience of about 40 years. Currently, he is heading Bombay Chamber of Commerce and Industry, a premier Chamber of commerce as Director General. He is an eminent Chartered Accountant having more than 23 years of experience in the fields of Income Tax, Company Law, Banking, Finance, Statutory Audit, Internal Audit, Concurrent Audit, Special Task Audit, Tax Audit, Bank Audit, Financial Institutions Audit, Designing and developing Internal Control and Check Systems

• etc. He has been practicing as a Chartered

Accountant, in Mumbai, under the firm name Laxmikant Kabra & Co.

• Mr. Laxmikant Kabra

Non-Executive and Non-Independent Director

8

Diagnostic Reagents Cosmetics Pharmaceuticals Speciality Coatings Veternairy API Catalysis Glass & Ceramics Electronics Synthetic Fibers Electroplating Resolving Agents Feed Nutrients

Segments Served

9

Evolution Of Company

2015

• Commercialization of 300 MTPA capacity at Unit VI at Chiplun

FY 1983

• Incorporated as a proprietary firm at Badlapur; Develops import substitutes - molybdenum and selenium derivatives

1995

• Starts producing a slew of Iodine derivatives

2000

• Launch of new product - Selenium Organic Intermediates

2005

• Incorporation of Omkar Speciality Chemicals Pvt. Ltd.

2006

• Takeover of the business of the proprietary firm having manufacturing operations of molybdenum, cobalt, selenium &

iodine derivatives (installed capacity at the time of 318 MT) 2009

• Commences operations at Unit II, F-24 at Badlapur (East), Thane District

2010

• A public limited company now, receives ISO 9001:2008 Certification for Unit II, FDA approval to manufacture Selenium

Sulphide USP in Unit III, B-34 at Badlapur; Sets up R&D center at Unit III 2011

• Commences operations at Unit III
• Lists on BSE and NSE through an Initial Public Offer
• Acquires Rishichem Research

2012

• Acquisitions of Desh Chemicals Pvt. Ltd., Urdhwa Chemicals Company Pvt. Ltd., Plot No. D-27/5, at Chiplun and Plot
• No. F-9 (adjacent to Unit IV at Badlapur) and receives DSIR recognition for R&D Center

2013

• Forays into API manufacturing through acquisition of Lasa Laboratory Pvt. Ltd.
• Acquires plot No. W-94(A) & W-95(A) adjacent to Unit I at Badlapur
• Successful commissioning of ERP and Urdhwa Chemicals Plant at Chiplun

2014

• Acquisition of Plot No. B-15 and B-16 at Chiplun, Plot No. D-27/4, adjacent to Unit V at Chiplun and Plot No. W-93(A)

adjacent to Unit I at Badlapur

10

Business Segments

Iodine Compounds Anti-diabetic, anti-cancer, anti-cholesterol, etc. & as diagnostic reagents Resolving Agents Used in separation of optical isomers during synthesis of bulk drugs Selenium Compounds Ingredient for feed nutrient, pharma intermediates, manufacture of tinted glasses and ceramics Intermediates Used in pharmaceutical industry in synthesis of various APIs particularly as oxidizing or reducing agents APIs Veterinary APIs used mostly as Anthelmintic (de-worming) 129.39 51.13 16.28 10.53 56.83 Product usage FY15 Revenue (Rs. Cr.)*

*Rest of the revenue amounting to ~Rs. 0.97 Cr is contributed by other products like derivatives of Molybdenum, Cobalt, Bismuth, etc.

11

Business Units

Badlapur Inorganic Intermediates Badlapur Unit II Organic Intermediates Badlapur Inorganic Intermediates Badlapur Centralised warehouse Unit I Unit III Unit IV Chiplun Organic Intermediates Chiplun Unit VI Organic Intermediates Mahad APIs (Veterinary) Chiplun Organic Intermediates Unit V Lasa

Urdhwa

Badlapur Pilot plant for product commercialization

Rishi chem

600 1,025 75 NA NA 300 450 2,800 NA

Unit Location Activity undertaken Volumetric Capacities*

*Volumetric capacities in MTPA as of March 31, 2015

TOTAL 5250

12

Capacity Growth Over The Years

Volumetric Capacity (MTPA) FY09 FY10 FY11 FY12 FY13 FY14 FY15 Unit I 375 375 375 600 600 600 600 Unit II 375 375 500 1,025 1,025 1,025 1,025 Unit III

• 75

75 75 75 75 Unit VI

• 300

Lasa

• 120

120 450 Urdhwa

• 2,800

2,800 2,800 Total Capacity 750 750 950 1,700 4,620 4,620 5,250

375 375 375 600 600 600 600 375 375 500 1,025 1,025 1,025 1,025 75 75 75 75 75

• 300

120 120 450 2,800 2,800 2,800 1000 2000 3000 4000 5000 6000 FY09 FY10 FY11 FY12 FY13 FY14 FY15 Unit I Unit II Unit III Unit VI Lasa Urdhwa

13

Strengths

Fungible Facilities leading to multi product capability Diversified customer base

• Manufacturing

facilities with multiple product capability

• Products across

segments comprise of more than 200 products

• OSCL can

change its product mix with minimum lead time Long standing existing client relationships

• Existing client

relationships in domestic and international markets

• Of the top 30

customers over the past 2 fiscal years, more than 40% have been repeat customers Cost advantage backed by a strong focus on R&D

• Developed

processes for manufacture of products in a cost effective manner

• DSIR recognized

R&D unit

• Acquired

Rishichem Research Limited – unit equipped with pilot plant facilities Quality control

• OSCL has

quality control departments at each of its units

• Activities

comprise sampling, testing of raw materials and processes, quality certification, etc. Experienced management team and employees

• Managed by a

team of qualified and experienced management and technical teams

• OSCL believes

that the strength and quality of its management team has been instrumental in implementing its business and growth strategies successfully

• Diverse

customer base from different industry segments

• In FY15, OSCL’s

top 30 customers contributed less than 60% of the total sales, with the largest customer contributing 6.03% of the total sales 1 2 3 4 5 6

14

Top Products (1/2)

Segments Iodine Compounds Intermediates Uses

• Reagent in pharma

industry

• Intermediate for API
• Screen printing
• Animal feed

formulations

• Digital applications
• Regent in pharma

industry

• Pigments
• Building block in
• rganic chemistry

Indicative Products per Segment and Segmental Sales (Rs.Cr.) FY14 FY15 3,5-Di Iodo Salicylic Acid 5-Iodo-2-Methyl Benzoic Acid Methyl Iodide Potassium Iodate Potassium Iodide Sodium Iodide Sodium Meta Periodate Tri Methyl Sulfoxonium Iodide Others 1,3-Acetone Di Carboxylic Acid 2,4 Di Chloro Benzoic Acid 4-Amino-2,4-Dichloro-5-Metildiphenil 4-Hydroxy-3 Iodo 5- Nitrobenonitile Crude 4-Iodoanisole Bismuth Oxide Phosphomolybdic Acid Tellurium Dioxide Vanadyl Sulphate Others 139.51 129.39 The sale of Iodine products in volume terms increased by 26.91% 41.26 51.13 Growth of 23.92% APIs

• Deworming for

veterinary purposes

• Anti-fungal for

veterinary purposes Albendazole Closantel Fenbendazole Nitroxynil Povidone Iodine Toldimfos Sodium Others 32.75 56.83 Growth of 73.53%

15

Top Products (2/2)

Segments Resolving Agents Others Uses

• Separation of optical

isomers

• Catalyst across

industries

• Feed additive

Indicative Products per Segment and Segmental Sales (Rs.Cr.) Di-Benzoyl L-Tartaric Acid (DBLTA) Di-p-Toluoyl D-Tartaric Acid (Anhydrous) Di-p-Toluoyl L-Tartaric Acid (Anhydrous) Others Ammonium Molybdate Cobalt Carbonate Sodium Molybdate Others 5.33 0.97 De-growth of 81.80% due to reducing focus

• n these highly

competitive markets 9.75 10.53 Growth of 8% Selenium Compounds

• Tinted glass manuf.
• Animal/Poultry feed
• Anti-Dandruff

Shampoo

• Reagent for API &

pharma industry FY14 FY15 Benzene Seleninic Anhydride Selenium Dioxide Selenium Sulfide Sodium Selenate Sodium Selenite Others 21.35 16.28 Decline of 23.75%

16

Markets Served

Currently OSCL has footprints across 38 countries round the globe

17

Strategy

• Increase in Gross margins
• Diversified portfolio along with Mix and match of commodity and speciality niche

molecules Augmenting manufacturing capacity to increase product range

• Exports have a shorter debtor cycle compared to domestic sales and will hence

help in improvement in Net Working Capital days

• Logistic costs will come down due to setting up of Antwerp warehouse

Increase in exports

• Receipt of process patents prohibits the use of the same process for manufacture
• f the said product by anyone else
• This will reduce competition for the products and increase margins as well as

payment terms

Process patents for key products

18

Strategy (continued)

• 1. Enable the Company to become cost competitive
• 2. Imported Raw Material Dependency is reduced
• 3. Improvement in working capital with lower dependence on customers

Focus on backward and forward integration

• 1. Focus on R&D will enable Company to have a steady growth in product pipeline
• 2. Helps OSCL to stand different than it’s Competitors and Highlights it’s technical

Expertise

Focus on innovation

• 1. Increase in margins
• 2. Further diversification of customer base
• 3. Such Diversified range of products helps OSCL to maintain its Top line and Bottom

Line

High margin niche products along with portfolio of high volume commoditized products

19

TECHNICAL EXPERTISE

Synthetic Lab:

• High pressure reactions (Hydrogenations / Carboxylations).
• 20°C to  200°C Reactions.
• Polymorphism.
• Handling Air and Moisture Sensitive Reactions / Reagents.
• Reactions Handled –
• Grignard Reactions,
• Nitration, Halogenation,
• Oxidation,
• Reduction,
• Esterification,
• Ammonolysis,
• Oximation,
• Acetylation,
• Alkylation, etc.

Analytical Lab:

• Analytical Method Development – In-process, Raw-Material, Intermediates &

Finished Products.

• Method Validation.
• Impurity Profiling.
• Stability Studies.

21

Why Are We In The Iodine Compounds Business?

Iodine Production and Demand Scenario  OSCL caters across all segments Iodine Commodity Derivatives Niche Derivatives Contrast Media (API) Repellents & Other Uses Recent Developments in Iodine Markets

• Iodine is supplied predominantly from 2 countries i.e. Japan and Chile
• The iodine market saw volatility in supply post 2010 due to the natural calamities in Japan, which pushed the prices up

 As a result prices increased from US$30 per kg to US$90 per kg and was stable around US$75 per kg levels

• In early FY 2014, Japanese supplies resumed and prices fell to US$30 per kg recently; with the market reaching normal

levels of operations Salient Features and Benefits of Iodine

• Used in production of many lifesaving drugs and is indispensible in most processes
• A vital ingredient for monitoring operations of thyroid gland; leading to an increase in demand of iodine and its

derivatives

• Iodine is used for the manufacture of diagnostic reagents, called contrast media in applications such as imaging,

scanning, etc., which has a vast potential to grow

22

Consolidated Financial Snapshot

Note: EBITDA calculated as PBT + Depreciation + Finance Costs – Other Income using the respective numbers for financial years 2012, 2013, 2014 and 2015 ended March 31

Revenue from Operations (Rs. Cr.) EBITDA (Rs. Cr.) PAT (Rs. Cr.) Net Worth (Rs. Cr.)

166.95 211.69 240.27 265.13 90.48 50 100 150 200 250 300 FY12 FY13 FY14 FY15 Q1 2016 33.19 40.17 42.94 52.17 17.26 10 20 30 40 50 60 FY12 FY13 FY14 FY15 Q1 2016 16.00 20.56 13.56 24.28 8.17 5 10 15 20 25 30 FY12 FY13 FY14 FY15 Q1 2016 105.43 127.06 137.21 168.57 176.74 20 40 60 80 100 120 140 160 180 200 FY12 FY13 FY14 FY15 Q1 2016

23

Key Ratios

ROE (%) ROCE (%)

15.18% 16.18% 9.88% 14.40% 0.00% 2.00% 4.00% 6.00% 8.00% 10.00% 12.00% 14.00% 16.00% 18.00% FY12 FY13 FY14 FY15 17.59% 17.24% 12.96% 13.82% 0.00% 2.00% 4.00% 6.00% 8.00% 10.00% 12.00% 14.00% 16.00% 18.00% 20.00% FY12 FY13 FY14 FY15

24

Key Ratios

Note: Calculated on the basis of Closing Balance of Accounts Receivables, Inventory and Accounts Payable with respect to Net Revenue from Operations

Working Capital Cycle

145 177 203 143 111

• 50

100 150 200 250 FY12 FY13 FY14 FY15 Q1 2016

25

Snapshot 2015

FY15 Revenue: Rs. 265.13 crore

129.39 16.28 51.13 56.83 0.97 10.53

Iodine Compounds Selenium Compounds Intermediates API Others (Molybdenum, Cobalt, Bismuth) Resolving Agents

26

Fast Growing Segments

Revenue – API Business (Lasa) (Rs. crore) Revenue – Exports (Rs. crore)

10.81 32.76 71 20 40 60 80 FY13 FY14 FY15

26.08 59.76 62.12 67.17

10 20 30 40 50 60 70 80 FY12 FY13 FY14 FY15

27

Quarterly Trend – Consolidated nos.

Note: EBITDA calculated as PBT + Depreciation + Finance Costs – Other Income using the respective first quarterly numbers for years 2014, 2015 and 2016 57.51 53.51 90.48

18.59% 16.29% 19.08% 5.62% 9.28% 9.03% 0.00% 5.00% 10.00% 15.00% 20.00% 25.00% 0.00 10.00 20.00 30.00 40.00 50.00 60.00 70.00 80.00 90.00 100.00

Q1FY14 Q1FY15 Q1FY16

• Rs. crore

Sales EBITDA Margin PAT Margin

BEST EMERGING SME AWARD, 2013 TO OSCL

Receipt of an Award by Mr. Pravin S. Herlekar,

• Mr. Pravin S. Herlekar, Promoter and Chairman & Managing Director of OSCL has been honored for his dedicated services to the

Chemical Industry and developing various molecules through research and development activity in this field, by Free Press Journal group, at the hands of Mr. Devendra Fadnavis, Chief Minister of State of Maharashtra, in the presence of Hon’ble Shri Ram Naik, Governor of State of Uttar Pradesh

THANK YOU Visit us at www.omkarchemicals.com